About Epiva Therapeutics
Epiva Therapeutics is a Healthcare company based in Cambridge (United States) founded in 2015, and was acquired by Evelo Biosciences in July 2016. Microbiome-based therapeutics are developed for autoimmune diseases. Its focus areas include Life Sciences, Immunology, Drugs and Diversified. Its competitors include Biogen, Insitro and BridgeBio; 3 of its 3 listed competitors have raised funding.
Company details
Epiva Therapeutics was founded in 2015 in Cambridge, United States, as a microbiome-focused company originating from Flagship VentureLabs. Operations center on the development of therapeutics targeting autoimmune diseases linked to microbiome dysbiosis. The sector involves biotechnology applications in gut microbiome modulation to address immune dysregulation. Research and therapeutic innovation are conducted in the United States, with a emphasis on clinical translation for dysbiosis-associated conditions.
- Headquarters Cambridge, United States
- Stage Acquired
- SectorsHealthcare
- Website epiva.com
- Social LinkedIn X
- Acquired by Evelo Biosciences (Jul 2016)
- Investors
- Acquired byEvelo Biosciences
(Jul 2016)
Investors in Epiva Therapeutics
Epiva Therapeutics has secured backing from 1 investor. Prominent investors backing the company include Evelo Biosciences.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Therapeutics for inflammatory diseases, COVID-19, and cancer are developed. | 2015 | evelobio.com | Cambridge, United States |
Investor details for Epiva Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Epiva Therapeutics
2 dated milestones of Epiva Therapeutics across 1 years, from founding to its latest funding, stage changes and deals.
- Founded Epiva Therapeutics is founded.
- Exit Acquired by Evelo Biosciences.
Competitors of Epiva Therapeutics
Epiva Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Biogen, Insitro and BridgeBio.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. | |
| insitro.com | 2018 | San Francisco, United States | $643.21M | 257 | An AI-enabled platform is developed for infectious disease treatment. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. |
Detailed competitors of Epiva Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Epiva Therapeutics (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Epiva Therapeutics
Epiva Therapeutics was founded in 2015.
Epiva Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Epiva Therapeutics was founded in 2015 in Cambridge, United States, as a microbiome-focused company originating from Flagship VentureLabs. Operations center on the development of therapeutics targeting autoimmune diseases linked to microbiome dysbiosis. The sector involves biotechnology applications in gut microbiome modulation to address immune dysregulation. Research and therapeutic innovation are conducted in the United States, with a emphasis on clinical translation for dysbiosis-associated conditions.
Epiva Therapeutics has 1 investor. Key investors include Evelo Biosciences.
Yes. Epiva Therapeutics was acquired by Evelo Biosciences in July 2016.
